Wuhan Hiteck Biological Pharma Co Ltd
300683
Company Profile
Business description
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Contact
Hite Science and Technology Park
Wuhan Economic and Technological Development Zone
Hubei Province
Wuhan430056
CHNT: +86 2784599931
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,309
Stocks News & Analysis
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,140.50 | 11.00 | 0.12% |
| CAC 40 | 7,656.10 | 42.82 | -0.56% |
| DAX 40 | 23,625.66 | 144.67 | -0.61% |
| Dow JONES (US) | 45,316.53 | 304.76 | -0.67% |
| FTSE 100 | 9,204.98 | 11.89 | -0.13% |
| HKSE | 25,417.98 | 359.47 | 1.43% |
| NASDAQ | 21,621.71 | 85.98 | -0.40% |
| Nikkei 225 | 43,018.75 | 438.48 | 1.03% |
| NZX 50 Index | 13,223.53 | 90.33 | 0.69% |
| S&P 500 | 6,464.58 | 37.50 | -0.58% |
| S&P/ASX 200 | 8,871.20 | 8.60 | 0.10% |
| SSE Composite Index | 3,812.51 | 46.64 | 1.24% |